ShigOraVax

Diarrhoeal Disease
Shigellosis

01 October 2019 to 30 September 2024

European Vaccine Initiative

EDCTP2

8.6 Mio Euro

SUMMARY

Early clinical development of an oral Shigella vaccine through phase II study in Africa

The ShigOraVax project aims at advancing the clinical development of a safe, efficacious and affordable Shigella vaccine. The project aims at developping oral Shigella vaccine called ‘ShigOraVax’ against three serotypes of Shigella flexneri (2a, 3a, and 6) as well as Shigella sonnei. Specific objectives of this project include (i) conduct of a phase Ia/b clinical trial in European and African adults followed by (ii) an age de-escalating phase II in Burkina Faso and a multi-centre phase IIb clinical trial in Burkina Faso and Zambia. Moreover, specific epidemiologic data will be generated on the incidence of Shigella disease in the two African countries among children under five. The results of this project will strengthen the vaccine pipeline against a major diarrhoeal disease and making it available for late stage clinical development.

https://www.shigoravax.org/

PARTNERS

Centre for Infectious Disease Research in Zambia (Zambia); European Vaccine Initiative (EVI) (Germany); Groupe de Recherche Action en Santé (GRAS) (Burkina Faso); Hilleman Laboratories (India); Leiden University Medical Center (LUMC) (Belgium); University of Gothenburg (Sweden).